Hemodialysis Access Blood Flow and Cardiopulmonary Outcomes

Arteriovenous (AV) access remains the cornerstone of long-term hemodialysis, yet it profoundly alters systemic hemodynamics. The resulting increase in venous return and cardiac output is initially adaptive but, when excessive, can precipitate maladaptive cardiovascular remodeling and downstream complications. A comprehensive literature search was performed using PubMed, Scopus, and Embase databases for studies published between 2018 and 2025. The search terms included <i>arteriovenous fistula</i>, <i>hemodialysis</i>, <i>high-output heart failure</i>, <i>pulmonary hypertension</i>, and <i>left-ventricular hypertrophy</i> (LVH). Due to the heterogeneity in design and the limited availability of randomized data, this paper was developed as a narrative synthesis rather than a formal systematic review. Arteriovenous access flow exceeding 1.5-2.0 L/min, a threshold that indicates excessive flow, or representing more than 25-30% of cardiac output, is strongly associated with an increased risk of left-ventricular hypertrophy (LVH), high-output heart failure (HOHF), and pulmonary hypertension (PH). This threshold serves as a crucial clinical marker, guiding the diagnosis and management of high-flow AV access complications. Diagnostic assessment should combine duplex ultrasonography, ultrasound dilution techniques, and echocardiography. Right-heart catheterization, a procedure that involves inserting a catheter into the right side of the heart to measure pressures and oxygen levels, is used to confirm the hemodynamic burden. Optimal management involves meticulous volume control, targeted pharmacologic therapy, and, when indicated, surgical or endovascular flow reduction. Arteriovenous access remains both a therapeutic necessity and a potential hemodynamic stressor. Consistent flow surveillance, periodic echocardiographic evaluation, and individualized access planning within the ESRD Life-Plan framework, a patient-centered care model that aligns access strategy with clinical status, lifestyle, and preferences, are essential for preventing irreversible cardiopulmonary remodeling and optimizing long-term clinical outcomes.